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eye disease). Transition probabilities and HbA1c-dependent
adjustments came from UKPDS and other major studies. Costs
of complications came from published sources. Direct costs of
diabetes complications and SMBG were projected over patients’
lifetimes from a UK National Health Service perspective. Out-
comes were discounted at 3.5% annually. Sensitivity analysis was
performed. RESULTS: Depending on the type of diabetes treat-
ment (diet and exercise/oral medications/insulin), improvements
in glycemic control with SMBG improved discounted QALYs 
by 0.12 ± 0.14 to 0.21 ± 0.14, with increased total costs of 
£603 ± 909 to £2240 ± 1124/patient, giving incremental cost-
effectiveness ratios of £4853 to £10,670/QALY gained, well
within current UK willingness-to-pay limits. At a threshold of
£30,000/QALY gained, there was a 78–85% probability that
SMBG would be considered cost-effective. SMBG was most cost-
effective in the subgroup of patients treated with diet and exer-
cise. CONCLUSIONS: Improvements in glycemic control with
interventions including SMBG improves patient outcomes with
an acceptable cost-effectiveness ratio in the UK setting.
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OBJECTIVES: Economic evaluations of diagnostic technologies
are less well established than for therapeutic technologies. The
objective of this study was to undertake a cost-effectiveness
analysis in German ofﬁce-based centres of diagnostic strategies
with and without DaTSCAN (123I-FP-CIT) SPECT imaging for
patients with clinically uncertain Parkinsonian syndromes (PS)
to distinguish between PS and essential tremor (ET), one of the
conditions most commonly misdiagnosed as Parkinson’s Disease.
We report initial analytic results based on ofﬁce-based expert
opinion. METHODS: A Markov model was developed to simu-
late the progression of a cohort of patients with clinically uncer-
tain PS who are managed in an ofﬁce-based centre based on
clinical judgment alone or receiving DaTSCAN. Health states
were deﬁned in terms of therapy (PS, ET, none) and underlying
conditions (PS, ET). The model estimated time on potentially
beneﬁcial therapy (PBT: e.g. PS therapy for underlying PS) and
patient management costs over 5 years. Model probability inputs
were from published studies and treatment patterns/resource use
from a panel of German neurologists. Unit costs were from ofﬁ-
cial sources. The cost of a DaTSCAN test (agent plus adminis-
tration) was €929. A total of 40–60% cohort members were
assumed to have underlying PS. DaTSCAN sensitivity and speci-
ﬁcity were 95%/100% (institutional read) and 93%/97%
(blinded read). RESULTS: At 50% underlying prevalence and in
the absence of DaTSCAN, 25% of cohort members had PBT at
the outset, rising to 60% at 6 months and 62% at 5 years. Using
DaTSCAN, 99% of patients had PBT at the outset reducing to
79% at 5 years. DaTSCAN use generated an incremental 1.4 PB
years per patient, and 5-year costs were €795 lower for the
DaTSCAN group. CONCLUSION: Adding non-invasive
imaging to the management of patients with clinically uncertain
PS may be considered to be a cost-saving strategy with an
increase in time on potentially beneﬁcial therapy.
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OBJECTIVES: Cost-consequence analysis of a RP (remifentanil
+ propofol) regimen versus a conventional, commonly used MF
(midazolam + fentanyl) regimen for sedation of mechanically
ventilated postoperative cardiac surgery patients. METHODS:
We conducted a prospective, single-blinded, randomised cost-
consequence study with 80 patients in one German intensive care
unit (ICU). The RP group received remifentanil (6- max. 60mg
kg-1 h-1) and—if sedation at maximal remifentanil dose was
insufﬁcient—propofol (0.5–4.0mg kg-1 h-1). The MF group
received midazolam (0.02–0.2mgkg-1 h-1) and fentanyl (1.0–
7.0mgkg-1 h-1). Direct costs for drugs, material (variable costs
only), and staff were considered (hospital’s perspective, 2003
prices). Sensitivity and scenario analyses were performed with a
decision-analytic model. As the remifentanil dose in the study RP
regimen (baseline) was higher than in routine practice we simu-
lated a “routine practice” scenario: We lowered the mean
remifentanil infusion rate from 41.2mgkg-1 h-1 to 9mgkg-1 h-1,
increased the propofol infusion rate from 2.2mgkg-1 h-1 to 4mg
kg-1 h-1 and assumed that this scenario would have rendered the
same reduction (24%) in staff costs compared to MF regimen
and identical material and drug utilisation (except RP) as at base-
line. RESULTS: Compared to MF regimen, RP regimen (base-
line) led to a signiﬁcantly shorter mechanical ventilation time
(3.5h) and earlier discharge from ICU (18.3h) and equal average
net costs of €1700 for the ICU stay per patient. The routine prac-
tice scenario rendered 53% lower RP medication costs than base-
line thus yielding net savings of €200 per patient. These results
are sensitive to staff and drug cost variations. CONCLUSIONS:
Analysis indicates that RP regimen dominates MF regimen in the
investigated setting as it reduces the mechanical ventilation time
and hence the risk of ventilator-associated morbidity at equal
costs (baseline) or even savings (scenario).
Clinical Outcomes Studies
CO1
VALIDATION OF DIAGNOSTIC PROCEDURES IN
SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA.
CONCORDANCE BETWEEN INITIAL AND FINAL DIAGNOSIS
IN DAILY CLINICAL PRACTICE
Carballido J1, Badia X2, Gimeno A3, Regadera L4, Dal-Re R5,
Guilera M6
1Hospital Puerta de Hierro, Madrid, Spain; 2Health Outcomes
Research Europe Group, Barcelona, Cataluña, Spain; 3Hospital General
La Mancha, Ciudad Real, Spain; 4GlaxoSmith Kline, Madrid, Spain;
5GlaxoSmithKline, Madrid, Spain; 6Health Outcomes Research Europe,
Barcelona, Spain
OBJECTIVE: To assess the usefulness of daily practice diagnos-
tic methods (medical history, I-PSS questionnaire, digital rectal
examination (DRE) and prostate-speciﬁc antigen (PSA)) for the
diagnosis of Benign Prostatic Hyperplasia (BPH). METHODS:
A total of 363 consecutive patients with suspected BPH seen at
urological outpatient clinics, between April and November 2003,
participated in the study. The following steps were sequentially
followed to deﬁne the Initial Diagnosis: 1) medical history; 2) I-
PSS questionnaire; 3) DRE; and 4) PSA. It was then compared
to the Final Diagnosis (gold-standard) after step 5) urinary sed-
iment, residual volume and prostate size by ultrasonography, and
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urinary ﬂow rate. Physician’s diagnosis according to their expe-
rience, was recorded after each step A descriptive analysis was
conducted and validity and concordance were measured between
strategies. RESULTS: A total of 356 patients, mean age (SD) of
65.2 (8.4) years, with suspected BPH participated in the study.
Sensitivity, speciﬁcity, positive predictive value and negative pre-
dictive value were 91%, 65%, 95% and 50%, respectively. Per-
centage of agreement and kappa index between initial and ﬁnal
diagnosis were 87.9% and 0.5, respectively. CONCLUSIONS:
Concordance between initial diagnosis based on medical history,
I-PSS questionnaire, DRE and PSA with ﬁnal diagnosis of BPH
was high. This group of diagnostic procedures may be recom-
mended for BPH initial diagnosis in daily practice.
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OBJECTIVES: Despite current diabetes guidelines recommend-
ing increasingly stringent HbA1c targets, in the US approxi-
mately 60% of subjects are not controlled to target HbA1c
< 7%, with a typical 5-year delay. The purpose of this analysis
was to evaluate the effect of early achievement of glycemic
control on diabetes-related complications and costs.
METHODS: The Archimedes model was used to conduct a sim-
ulated clinical trial using patient-speciﬁc US NHANES data to
determine patient characteristics, current levels of glycemic
control and other CAD risk factors in people with diabetes. Sub-
jects with HbA1c > 7% were randomly assigned to four man-
agement strategies: status quo (SQ; maintaining current levels of
HbA1c but good compliance to guidelines for other CAD risk
factors), and reaching mean HbA1c < 7% within 6 months (MO),
12MO, or 24MO. The analysis focused on microvascular out-
comes. RESULTS: The model predicted that reducing HbA1c to
<7% in currently uncontrolled subjects would reduce the risk of
microvascular disease compared with SQ. Reaching HbA1c < 7%
within 6MO would reduce the 20-year risks of proteinuria
(52%), ESRD (44%, approximately 20,000 US cases prevented
p.a.), eye surgery (73%) and blindness (73%, approximately
17,500 cases prevented) compared with SQ. However, compared
with reaching HbA1c < 7% within 6MO, delaying to 24MO
increases these risks by 15%, 16%, 41% and 47%, respectively,
resulting in 3900 and 3000 more cases of ESRD and blindness,
respectively. Reaching target within 6MO would save approxi-
mately $2.3 billion p.a. compared with SQ. Delaying reaching
HbA1c < 7% to 24MO decreases these savings by approximately
$430 million. Beneﬁts were greater in patients with mean base-
line HbA1c > 9%. CONCLUSIONS: The Archimedes model pre-
dicts that in uncontrolled subjects, achieving HbA1c < 7% within
6MO would have important effects on microvascular outcomes
and costs. Delaying control to 24MO would reduce the amount
of beneﬁt gained. Bringing currently uncontrolled people into
control is important and should be achieved as rapidly as clini-
cally feasible.
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OBJECTIVES: Several trials of atomoxetine for the treatment of
attention deﬁcit hyperactivity disorder (ADHD) have employed
an active comparator arm of methylphenidate (MPH). This study
estimated efﬁcacy of atomoxetine and MPH in treating children
and adolescent with ADHD using combined patient-level data
from multiple trials. METHODS: Five randomized atomoxetine
trials contained an active comparator arm of MPH. Pooling of
all available data resulted in total 1078 patients, with 562 on
atomoxetine, 327 on MPH, and 189 on placebo. Because trials
excluded known non-responders to stimulant, stimulant exposed
patients may have a bias in favor of MPH. Subgroup analyses
were performed by stimulant history. The meta-regression is set
up as logistic regression for response. Response was deﬁned as
a ≥25% reduction in ADHD Rating Scale. In addition to treat-
ments, patient age, sex, duration of therapy, and trial effects were
controlled for. Random effect model was also estimated, but
ﬁxed effect was chosen. RESULTS: Response rates for stimulant
naïve patients were: 70.51% for atomoxetine, 77.27% for MPH,
and 41.46% for placebo. Response rate for each active treatment
was signiﬁcant, and signiﬁcantly different from placebo (p <
0.001). However, the two treatments were not statistically dif-
ferent by difference in means test (p = 0.069). In the exposed
group, response rates were: 62.17% for atomoxetine, 70.03%
for MPH, and 29.42% for placebo. Response rate for each active
treatment was signiﬁcant, and signiﬁcantly different from
placebo (p < 0.001). Difference between the two treatments, yet
again, was not statistically signiﬁcant (p = 0.214). CONCLU-
SION: To improve power and precision in the estimate, this
study pooled all available patient-level data from ﬁve random-
ized trials, and estimated response rate using the meta-regression
method. Efﬁcacy of atomoxetine and MPH were signiﬁcantly dif-
ferent from placebo. While response rate was higher for MPH,
response rates of the two active treatments were not statistically
different from each other.
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OBJECTIVE: To identify independent risk factors for renal
impairment in HRPC patients receiving ZA, we compared 
logistic regression and Cox proportional hazards models.
METHODS: A comprehensive medical record review was per-
formed, using electronic databases and paper records, in a large
tertiary oncology center. Inclusion criteria: ≥18 years, actively
treated, HRPC with BM, at least one ZA infusion (from 12/1999
to 4/2005), and at least one creatinine reading before and after
ﬁrst ZA infusion. Renal impairment was deﬁned as an increase
of ≥0.5mg/dL and ≥1.0mg/dL over baseline serum creatinine if
baseline was <1.4mg/dL and ≥1.4mg/dL, respectively; or any
doubling of baseline creatinine. Risk factor analysis was by logis-
tic regression with time adjustment, and by Cox model for time-
related binary outcome data. RESULTS: Among the 122 eligible
patients (mean age = 70.1), mean ZA treatment lasted 367.2 days
(mean 10.7 infusions per patient). About 59% of patients dis-
continued ZA; 21% due to renal complications. Twenty-nine
patients (23.8%, 95% CI: 16.2–31.3%) had renal impairment
during treatment; this is higher than previously reported in clin-
ical trials. Renal risk increased with extended ZA therapy (<6
months: 22.5%; ≥12 months: 23.5%; ≥24 months: 31.3%) and
